Fresenius confirms FY25 guidance

Published 07/05/2025, 09:40
Fresenius confirms FY25 guidance

Investing.com -- Fresenius, the global healthcare group, confirmed its financial guidance for FY25. The company’s shares saw a slight increase of 0.7% in early trading following this announcement.

The group’s revenue is expected to see an organic growth of 4-6%. The consensus estimate was 5.5%. The company’s adjusted EBIT is projected to grow 3-7% on a constant exchange rate (CER) basis, however, no specific EBIT margin target was provided. The consensus estimate for the EBIT margin was 11.5%, while Jefferies expected it to be 11.4%.

Fresenius Kabi, the company’s pharmaceutical and medical devices division, is expected to see mid to high single-digit organic growth, compared to the consensus estimate for this growth was 6.6%%. The adjusted EBIT margin for Kabi is projected to be 16-16.5%, with the consensus at 16.3%. The structural EBIT band for this division is 16-18%.

The company’s Helios division is projected to see mid-single-digit organic growth. The consensus estimate for this growth was 5.0%. The adjusted EBIT margin for Helios is expected to be around 10%, with the consensus estimating it to be 9.9% and Jefferies estimating it to be 9.8%.

The company’s leverage is projected to be 2.5-3.0x. The dividend policy of the company is to distribute 30-40% of the core net income. The company’s interest expense is expected to be €370m to €390m, which is a reduction from the previous estimate of €400m to €420m.

In the first quarter of FY25, the group’s revenue was €5,631m, slightly above the consensus estimate of €5,613m. This represented an organic growth of around 7%, which was higher than the consensus estimate of 6.1%. The adjusted EBIT for the quarter saw a CER growth of 4% with an 11.6% margin, which was higher than the consensus estimate of 11.3%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.